- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02915757
Electrodermal Hyporeactivity And Depression (EUDOR-A)
Naturalistic Clinical Studies in Several Centres of Electrodermal Hyporeactivity in Adult Patients With Primary Depression
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This EUDOR-A study is a naturalistic, european and multicentric study. In France, patient's recruitment will be only conducted by investigators within the Department of Psychiatric Emergencies and Post Acute Care, University Hospital of Montpellier.
Over one year, 233 patients suffering from a major depressive episode with (n=70) and without any history of suicide attempt (n=163) will be recruited.
The maximum period of participation for a given patient will be 12 months with 2 phone assessments at 6 month and 12 month.
Inclusion visit: clinical and biological assessment and Edor test. Second and third visits at 6 and 12 month: Follow up visits in the department or interview by telephone in order to assess suicidal ideations or suicide attempts since the inclusion.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Montpellier, France, 34295
- Montpellier University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria:
All subjects men and women will necessarily meet the following inclusion criteria:
- In- and outpatients, with a diagnosis of primary depression according to the International classification of Disease (ICD-10) should be included as a routine. That is, patients in a primary unipolar major episode or dysthymia or primary depression with a personality disorder or an anxiety disorder as secondary diagnoses and primary bipolar disorder in a non-hypomanic and non-manic phase are expected to be included.
- Age : 18 years or older
- written informed consent
- must belong to social safety system
- To be able to understand instructions for the EDOR Test, the aim and the methodology of the study.
Exclusion criteria:
- diagnosed or suspected dementia
- Acute known or suspected alcohol or other substance abuse. The condition of past substance abuse (i.e. alcohol abuse or dependance, drug abuse or dependance ) should be noted in the comment field of the EDOR Test routine and patient must have been abstinent for at least one year.
- Serious problems of hearing, the patient should not participate.
- Refusal of participation
- Subject deprived of liberty (by judicial or administrative decision)
- Subject protected by law.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Depressive patients
EDOR test on depressed patients with or without personal history of suicidal behavior
|
The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity. The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done. Blood sample and clinical assessment |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Specificity and sensibility of the electrodermal hyporeactivity
Délai: At 6 and 12 month
|
Correlation between the Edor Test results and suicidal behavior
|
At 6 and 12 month
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Délai: At 6 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 month
|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Délai: At 6 and 12 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 and 12 month
|
Electrodermal activity in depressive and suicidal patients with or without insomnia.
Délai: At 6 and 12 month
|
Comparison of test result between patients with insomnia and patient without insomnia.
Insomnia will be evaluated with the "Insomnia severity index" (ISI).
|
At 6 and 12 month
|
Genetic vulnerability to suicidal behavior by polymorphism analysis in blood sample
Délai: At the inclusion
|
To study the polymorphisms by blood sample analysis of the promotor of Spermidine/Spermine Acetyltransferase 1 (SAT1), Phenylethanolamine N-Methyltransferase (PNMT) and Noradrenalin Transporter (NAT).
between depressed patients with suicidal behavior and depressed patients without suicidal behavior.
|
At the inclusion
|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Risk Rescue Rating Scale (RRRS)
Délai: At 6 and 12 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 and 12 month
|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Beck Scale for Suicidal Intent (SIS).
Délai: At 6 and 12 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 and 12 month
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- UF 9464
- 2014-A01310-47 (Autre identifiant: Agence Nationale de sécurité des Médicaments)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur EDOR test
-
Guven Health GroupComplétéPerformance athlétique | Forme physique | Handballeurs | Études transversalesTurquie
-
The Hospital for Sick ChildrenComplété
-
Coloplast A/SComplété
-
Coloplast A/SComplété
-
M.D. Anderson Cancer CenterInconnueCancer du poumonÉtats-Unis
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityChanghai Hospital; Tianjin Nankai HospitalRecrutementCancer colorectal | Polype adénomateux colorectalChine
-
Józef Piłsudski University of Physical EducationComplétéCécité | Déficience visuellePologne
-
First Hospital of China Medical UniversityRecrutementTumeurs de l'estomac | MétastaseChine
-
Genomind, LLCComplétéUne étude ouverte sur l'utilité clinique et les résultats pour les patients du test Genecept (COM-1)Désordre anxieux généralisé | Dépression résistante au traitementÉtats-Unis
-
Hospital Clínica KennedyComplétéAccident vasculaire cérébral | Insomnie | La cardiopathie ischémique | Troubles respiratoires du sommeil | HypersomnieEquateur